Scholar Rock resubmits EMA MAA for apitegromab with new fill-finish site

Scholar Rock resubmitted its apitegromab MAA to the EMA, replacing the prior Catalent Indiana fill-finish site with an alternate facility and expecting a CHMP opinion in H1 2027.